ESSA Pharma Inc Cash Flow Conversion Efficiency
ESSA Pharma Inc cash flow conversion efficiency. Based on the latest financial reports, ESSA Pharma Inc (EPIX) has a cash flow conversion efficiency ratio of -0.039x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.20 Million) by net assets ($108.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of ESSA Pharma Inc (2012–2024)
Cash flow conversion efficiency of ESSA Pharma Inc from 2012 to 2024. This chart illustrates how ESSA Pharma Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View EPIX live share price for real-time trading data and today's change.
ESSA Pharma Inc Cash Flow Conversion Ratio Explained
ESSA Pharma Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
ESSA Pharma Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of ESSA Pharma Inc ranked by their cash flow conversion efficiency. Also see ESSA Pharma Inc (EPIX) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
RS Public Company Limited
BK:RS
|
-0.029x |
|
Pan Entertainment Co. Ltd
KQ:068050
|
0.057x |
|
Zhuhai Sailong Pharmaceutical Co Ltd
SHE:002898
|
-0.076x |
|
Agrimin Ltd
AU:AMN
|
-0.039x |
|
Investcorp Credit Management BDC Inc
NASDAQ:ICMB
|
0.187x |
|
VL E-Governance & IT Solutions Limited
NSE:VLEGOV
|
N/A |
|
Tian An Australia Ltd
AU:TIA
|
0.083x |
|
Vaishali Pharma Limited
NSE:VAISHALI
|
0.030x |
Annual Cash Flow Conversion Efficiency for ESSA Pharma Inc (2012–2024)
The table below shows the annual cash flow conversion efficiency of ESSA Pharma Inc from 2012 to 2024. Review ESSA Pharma Inc (EPIX) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | $124.61 Million | $-22.72 Million | -0.182x | -34.21% |
| 2023-09-30 | $145.63 Million | $-19.78 Million | -0.136x | +20.91% |
| 2022-09-30 | $167.12 Million | $-28.70 Million | -0.172x | -31.11% |
| 2021-09-30 | $194.01 Million | $-25.42 Million | -0.131x | +38.87% |
| 2020-09-30 | $79.24 Million | $-16.98 Million | -0.214x | +13.96% |
| 2019-09-30 | $49.18 Million | $-12.25 Million | -0.249x | +77.69% |
| 2018-09-30 | $9.15 Million | $-10.22 Million | -1.116x | -127.50% |
| 2017-09-30 | $-4.27 Million | $-17.35 Million | 4.061x | -85.75% |
| 2016-09-30 | $-537.00K | $-15.30 Million | 28.493x | +1125.81% |
| 2015-09-30 | $4.43 Million | $-12.30 Million | -2.778x | -163.48% |
| 2014-09-30 | $1.97 Million | $-2.08 Million | -1.054x | -66058.28% |
| 2013-09-30 | $479.04K | $-763.35 | -0.002x | +99.89% |
| 2012-09-30 | $1.31K | $-1.82K | -1.396x | -- |
About ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company was incorporated in 2009 and is headquartered in Vancouver, Canada. As of October 9, 2025, ESSA Pharma Inc. operates as a subsidiary of Alexis Bio, Inc.